GLPwatch
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
NCT00508287 · Completed
Last updated 2026-05-28This clinical trial tests the safety and effects of the drug BMS-686117 in people with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 36 people Planned (estimated).
Who can join Ages 18–70 · all sexes
Timeline Started 2007-08 · est. completion 2007-11
Where 3 sites · United States
What this study is testing ClinicalTrials.gov NCT00508287 ↗
Description as written by the study sponsor.
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117
Treatments tested
- BMS-686117 Drug
Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
- Byetta Drug
Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
- Placebo Drug
Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
| Main thing measured | Safety: incidence of adverse events |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00508287 ↗